Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah M Schwarzenböck

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|May 16, 2020
Highlights of the 32th Annual Congress of the EANM, Barcelona 2019: the nucleolympic games of nuclear medicine-a global competition for excellenceSarah M Schwarzenböck, Valentina Garibotto
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|June 29, 2020
FDG PET Hybrid ImagingJuliane Becker, Sarah M Schwarzenböck, Bernd J Krause
European Journal of Nuclear Medicine and Molecular Imaging|September 5, 2019
First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [<sup>177</sup>Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancerJens Kurth, Bernd Joachim Krause, Sarah M Schwarzenböck, et al.
Nuclear Medicine Communications|January 10, 2018
Peptide receptor radionuclide therapy with 177Lu-DOTA-octreotate: dosimetry, nephrotoxicity, and the effect of hematological toxicity on survivalAnastassia Löser, Sarah M Schwarzenböck, Martin Heuschkel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 4, 2016
Evaluation of Prostate Cancer with 11C- and 18F-Choline PET/CT: Diagnosis and Initial StagingSascha Nitsch, Oliver W Hakenberg, Martin Heuschkel, et al.
Cancers|August 7, 2021
Streamlined Schemes for Dosimetry of <sup>177</sup>Lu-Labeled PSMA Targeting Radioligands in Therapy of Prostate CancerJens Kurth, Martin Heuschkel, Alexander Tonn, et al.
Nuklearmedizin. Nuclear Medicine|March 15, 2018
[18F]FDG PET/CT for assessing inguinal lymph nodes in patients with penile cancer - correlation with histopathology after inguinal lymphadenectomyDesiree L Dräger, Martin Heuschkel, Chris Protzel, et al.
Healthcare (Basel, Switzerland)|May 10, 2024
Patient-Orientated Evaluation of Treatment of Non-Melanoma Skin Cancer with Rhenium-188 Compared to SurgeryMaila I C Krönert, Sarah M Schwarzenböck, Jens Kurth, et al.
Scientific Reports|October 16, 2020
Anatomical MRI and [<sup>18</sup>F]FDG PET/CT imaging of Schistosoma mansoni in a NMRI mouse modelTobias Lindner, Jan Stenzel, Nicole Koslowski, et al.
Nuclear Medicine Communications|August 23, 2021
Evaluation of [68Ga]Ga-PSMA PET/CT for therapy response assessment of [177Lu]Lu-PSMA radioligand therapy in metastasized castration refractory prostate cancer and correlation with survivalJens Kurth, Justus Kretzschmar, Hamzeh Aladwan, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
European Journal of Nuclear Medicine and Molecular Imaging|May 16, 2020
Highlights of the 32th Annual Congress of the EANM, Barcelona 2019: the nucleolympic games of nuclear medicine-a global competition for excellenceSarah M Schwarzenböck, Valentina Garibotto
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|June 29, 2020
FDG PET Hybrid ImagingJuliane Becker, Sarah M Schwarzenböck, Bernd J Krause
European Journal of Nuclear Medicine and Molecular Imaging|September 5, 2019
First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [<sup>177</sup>Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancerJens Kurth, Bernd Joachim Krause, Sarah M Schwarzenböck, et al.
Nuclear Medicine Communications|January 10, 2018
Peptide receptor radionuclide therapy with 177Lu-DOTA-octreotate: dosimetry, nephrotoxicity, and the effect of hematological toxicity on survivalAnastassia Löser, Sarah M Schwarzenböck, Martin Heuschkel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 4, 2016
Evaluation of Prostate Cancer with 11C- and 18F-Choline PET/CT: Diagnosis and Initial StagingSascha Nitsch, Oliver W Hakenberg, Martin Heuschkel, et al.
Cancers|August 7, 2021
Streamlined Schemes for Dosimetry of <sup>177</sup>Lu-Labeled PSMA Targeting Radioligands in Therapy of Prostate CancerJens Kurth, Martin Heuschkel, Alexander Tonn, et al.
Nuklearmedizin. Nuclear Medicine|March 15, 2018
[18F]FDG PET/CT for assessing inguinal lymph nodes in patients with penile cancer - correlation with histopathology after inguinal lymphadenectomyDesiree L Dräger, Martin Heuschkel, Chris Protzel, et al.
Healthcare (Basel, Switzerland)|May 10, 2024
Patient-Orientated Evaluation of Treatment of Non-Melanoma Skin Cancer with Rhenium-188 Compared to SurgeryMaila I C Krönert, Sarah M Schwarzenböck, Jens Kurth, et al.
Scientific Reports|October 16, 2020
Anatomical MRI and [<sup>18</sup>F]FDG PET/CT imaging of Schistosoma mansoni in a NMRI mouse modelTobias Lindner, Jan Stenzel, Nicole Koslowski, et al.
Nuclear Medicine Communications|August 23, 2021
Evaluation of [68Ga]Ga-PSMA PET/CT for therapy response assessment of [177Lu]Lu-PSMA radioligand therapy in metastasized castration refractory prostate cancer and correlation with survivalJens Kurth, Justus Kretzschmar, Hamzeh Aladwan, et al.
Pageof 3